Holen Sie sich die Stockscreener-App
75.29
2.36%
-1.9646
Schlusskurs vom Vortag:
$77.25
Offen:
$76.78
24-Stunden-Volumen:
1.54M
Relative Volume:
0.69
Marktkapitalisierung:
$14.52B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-31.24
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+2.73%
1M Leistung:
+0.37%
6M Leistung:
+62.31%
1J Leistung:
+159.38%
1-Tages-Spanne:
$70.95
$76.78
1-Wochen-Bereich:
$70.95
$78.36
52-Wochen-Spanne:
$28.10
$78.58
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
75.35 | 14.89B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.95 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.21 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
777.67 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.35 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.82 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio reports $362.4 million in 2025 Attruby revenue By Investing.com - Investing.com UK
BridgeBio (BBIO) Highlights Strategic Advancements at Healthcare Conference - GuruFocus
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th ... - Bluefield Daily Telegraph
New genetic treatments move closer for heart and rare childhood diseases - Stock Titan
Sectors Review: Is BridgeBio Pharma Inc in a bullish channelM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Wrap: What makes BridgeBio Pharma Inc stock attractive to growth fundsQuarterly Market Summary & Risk Managed Investment Signals - moha.gov.vn
Will BridgeBio Pharma Inc. stock benefit from commodity prices2025 Dividend Review & Daily Profit Maximizing Tips - ulpravda.ru
What hedge fund activity signals for BridgeBio Pharma Inc. stockMarket Sentiment Report & Weekly Chart Analysis and Guides - ulpravda.ru
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
Discipline and Rules-Based Execution in BBIO Response - Stock Traders Daily
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 StudySlideshow (NASDAQ:BBIO) 2026-01-09 - Seeking Alpha
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BBIO: Infigratinib shows strong efficacy and safety in achondroplasia, with high market adoption potential - TradingView — Track All Markets
Can BridgeBio Pharma Inc. stock hit record highs againJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - ulpravda.ru
What makes BridgeBio Pharma Inc. stock attractive to growth fundsQuarterly Earnings Summary & Verified Momentum Watchlists - ulpravda.ru
Why BridgeBio Pharma Inc. stock could rally in 2025Quarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
BridgeBio Pharma, Inc.Common Stock (NQ: BBIO - FinancialContent
How BridgeBio Pharma Inc. stock compares to industry benchmarksQuarterly Profit Review & Free Long-Term Investment Growth Plans - ulpravda.ru
Is BridgeBio Pharma Inc. stock a bargain at current levels2025 Risk Factors & Weekly High Return Forecasts - ulpravda.ru
How BridgeBio Pharma Inc. stock reacts to oil prices2025 Pullback Review & Fast Entry Momentum Trade Alerts - ulpravda.ru
BBIO: Truist Securities Raises Price Target to $86, Maintains Bu - GuruFocus
Will BridgeBio Pharma Inc. stock benefit from green energy trendsCPI Data & Fast Entry Momentum Trade Alerts - ulpravda.ru
Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Intratumoral Cancer Therapies Market Expected to Reach US$ - openPR.com
Morgan Stanley initiates coverage of BridgeBio Pharma (BBIO) with overweight recommendation - MSN
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge - Yahoo Finance
BBIO's Analyst Rating: Morgan Stanley Initiates Coverage with Ov - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Morgan Stanley - MarketBeat
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says - marketscreener.com
Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target - marketscreener.com
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating By Investing.com - Investing.com Canada
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 6.5%Should You Sell? - MarketBeat
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms - TechStock²
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
PRN_FinancialWrapper | PR NewswireBridgeBio to Participate in the J.P. Morgan Healthcare Conference - FinancialContent
BridgeBio Pharma stock hits all-time high at 78.46 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.46 USD - Investing.com
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - The Manila Times
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Earnings Notes - Trefis
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Behavioral Patterns of BBIO and Institutional Flows - Stock Traders Daily
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Aug Chart Watch: How BridgeBio Pharma Inc stock compares to industry benchmarksWeekly Trend Summary & Precise Trade Entry Recommendations - moha.gov.vn
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):